dc.contributor.author | Berkun, Y. | |
dc.contributor.author | Wason, S. | |
dc.contributor.author | Brik, R. | |
dc.contributor.author | Butbul, Y. | |
dc.contributor.author | Ben-Chetrit, E. | |
dc.contributor.author | Hashkes, P. J. | |
dc.contributor.author | Livneh, A. | |
dc.contributor.author | Ozen, Seza | |
dc.contributor.author | Ozdogan, H. | |
dc.contributor.author | Faulkner, R. | |
dc.contributor.author | Davis, M. W. | |
dc.date.accessioned | 2019-12-10T10:50:05Z | |
dc.date.available | 2019-12-10T10:50:05Z | |
dc.date.issued | 2012 | |
dc.identifier.issn | 0394-6320 | |
dc.identifier.uri | https://doi.org/10.1177/039463201202500429 | |
dc.identifier.uri | http://hdl.handle.net/11655/14309 | |
dc.description.abstract | This study sought to determine the appropriate starting dose of colchicine in children aged 2 to 4 years with familial Mediterranean fever (FMF) based on steady-state pharmacokinetics in pediatric patients with FMF >= 2 to <16 years and adult patients with FMF >= 16 to <= 65 years. Outpatients received colchicine for 90 days starting with a fixed dose for 14 days (blood sampling days 14 and 15). After starting doses of colchicine (0.6 mg/day [>= 2 to <4 years], 0.9 mg/day [>= 4 to <6 years], 0.9 mg/day [>= 6 to <12 years], 1.2 mg/day [>= 12 to <16 years], and 1.2 mg/day [>= 16 to <= 65 years]), the observed steady-state pharmacokinetic parameters were comparable across age groups, despite the higher doses of colchicine on a mg/kg/day basis in the younger age groups. An exception occurred with once-daily colchicine, whereby mean C-max for colchicine was higher in patients 4 to <6 years (9.4 ng/mL) compared with the younger and older age groups (6.1-6.7 ng/mL). Mean AUC(0_24h) values in children 2 to <4, 6 to <12, and 12 to <16 years were similar to those in adults. However, mean AUC(0_24h) values in children 4 to <6 years were 25% higher than those observed in adults. The results show that the recommended starting dose for children 2-4 years and 4-6 years should be 0.6 mg/day (half the US adult dose). Children aged 6 to <12 years should receive 0.9 mg/day (i.e. three-quarters of the US adult dose). The safety of colchicine in children 2 to <4 years was comparable to that in older children and adults. | |
dc.language.iso | en | |
dc.publisher | Biolife Sas | |
dc.relation.isversionof | 10.1177/039463201202500429 | |
dc.rights | info:eu-repo/semantics/openAccess | |
dc.subject | Immunology | |
dc.subject | Pathology | |
dc.subject | Pharmacology & Pharmacy | |
dc.title | Pharmacokinetics of Colchicine in Pediatric and Adult Patients with Familial Mediterranean Fever | |
dc.type | info:eu-repo/semantics/article | |
dc.type | info:eu-repo/semantics/publishedVersion | |
dc.relation.journal | International Journal Of Immunopathology And Pharmacology | |
dc.contributor.department | Çocuk Sağlığı ve Hastalıkları | |
dc.identifier.volume | 25 | |
dc.identifier.issue | 4 | |
dc.identifier.startpage | 1121 | |
dc.identifier.endpage | 1130 | |
dc.description.index | WoS | |
dc.description.index | Scopus | |